SAGE Therapeutics Inc (NASDAQ:SAGE) had its price objective boosted by HC Wainwright to $86.00 in a research note issued to investors on Friday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential downside of 1.15% from the company’s previous close.

Several other research analysts have also commented on SAGE. BidaskClub lowered SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. BMO Capital Markets restated a “buy” rating and set a $82.00 target price on shares of SAGE Therapeutics in a research note on Friday, July 28th. Cowen and Company assumed coverage on SAGE Therapeutics in a research note on Monday, June 12th. They set an “outperform” rating and a $95.00 target price on the stock. Canaccord Genuity restated a “buy” rating and set a $110.00 target price on shares of SAGE Therapeutics in a research note on Wednesday, May 10th. Finally, Bank of America Corporation assumed coverage on SAGE Therapeutics in a research note on Friday, May 12th. They set a “buy” rating and a $85.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $88.36.

SAGE Therapeutics (NASDAQ SAGE) traded up 10.97% during midday trading on Friday, hitting $87.00. The company had a trading volume of 1,099,824 shares. SAGE Therapeutics has a 52 week low of $35.02 and a 52 week high of $89.49. The stock’s market capitalization is $3.25 billion. The stock has a 50 day moving average price of $81.06 and a 200-day moving average price of $68.74.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by $0.25. During the same period in the previous year, the company earned ($1.08) earnings per share. On average, equities analysts predict that SAGE Therapeutics will post ($6.76) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “SAGE Therapeutics Inc (SAGE) Price Target Raised to $86.00” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/06/sage-therapeutics-inc-sage-price-target-raised-to-86-00.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in SAGE. Principal Financial Group Inc. increased its position in shares of SAGE Therapeutics by 1.1% in the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 62 shares during the period. State Board of Administration of Florida Retirement System increased its stake in SAGE Therapeutics by 5.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 12,742 shares of the biopharmaceutical company’s stock valued at $1,015,000 after buying an additional 686 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in SAGE Therapeutics by 2.5% in the second quarter. Essex Investment Management Co. LLC now owns 31,660 shares of the biopharmaceutical company’s stock valued at $2,521,000 after buying an additional 787 shares during the last quarter. Legal & General Group Plc increased its stake in SAGE Therapeutics by 9.5% in the first quarter. Legal & General Group Plc now owns 10,748 shares of the biopharmaceutical company’s stock valued at $755,000 after buying an additional 934 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in SAGE Therapeutics by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock valued at $9,342,000 after buying an additional 1,593 shares during the last quarter.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.